Quigley Pharma, Inc. – Product Pipeline Review – H2 2011

Date: October 1, 2011
Pages: 40
Price:
US$ 500.00 US$ 450.00
Offer valid until December 31, 2014!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: Q0BA218E207EN
Leaflet:

Download PDF Leaflet

Quigley Pharma, Inc. – Product Pipeline Review – H2 2011

Summary

Global Market Direct’s pharmaceuticals report, “Quigley Pharma, Inc. - Product Pipeline Review - H2 2011” provides data on the Quigley Pharma, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Quigley Pharma, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Quigley Pharma, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope
  • Quigley Pharma, Inc. - Brief Quigley Pharma, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
  • Review of current pipeline of Quigley Pharma, Inc. human therapeutic division.
  • Overview of pipeline therapeutics across various therapy areas.
  • Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
  • Product profiles for late stage and clinical stage products of Quigley Pharma, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
  • Recent updates of the Quigley Pharma, Inc.’s pipeline in the last quarter.
  • Key discontinued and dormant projects.
  • Latest news and deals relating to the products.
Reasons to buy
  • Evaluate Quigley Pharma, Inc.’s strategic position with total access to detailed information on its product pipeline.
  • Assess the growth potential of Quigley Pharma, Inc. in its therapy areas of focus.
  • Identify new drug targets and therapeutic classes in the Quigley Pharma, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
  • Exploit collaboration and partnership opportunities with Quigley Pharma, Inc..
  • Avoid Intellectual Property Rights related issues.
  • Explore the dormant and discontinued projects of Quigley Pharma, Inc. and identify potential opportunities in those areas.
Quigley Pharma, Inc. Snapshot
Quigley Pharma, Inc. Overview
Key Information
Key Facts
Quigley Pharma, Inc. – Research and Development Overview
Key Therapeutic Areas
Quigley Pharma, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Quigley Pharma, Inc. – Pipeline Products Glance
Quigley Pharma, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Quigley Pharma, Inc.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Quigley Pharma, Inc. – Drug Profiles

QR-336

Product Description
Mechanism of Action
R&D Progress

QR-340

Product Description
Mechanism of Action
R&D Progress

QR-435

Product Description
Mechanism of Action
R&D Progress

QR-440

Product Description
Mechanism of Action
R&D Progress

QR-446

Product Description
Mechanism of Action
R&D Progress
Quigley Pharma, Inc. – Pipeline Analysis
Quigley Pharma, Inc. – Pipeline Products by Therapeutic Class
Quigley Pharma, Inc. - Pipeline Products By Target
Quigley Pharma, Inc. – Pipeline Products by Route of Administration
Quigley Pharma, Inc. – Pipeline Products by Molecule Type
Quigley Pharma, Inc. - Dormant Projects
Quigley Pharma, Inc. – Locations And Subsidiaries
Head Office
Recent Developments
Jul 30, 2007: Quigley Begins Human Trial To Investigate Effects Of Broad Spectrum Anti-Inflammatory Compound On Metabolic Syndrome Patients
Apr 30, 2009: Unexpected Positive Finding Expands Potential For Quigley QR333 Drug For Diabetic Neuropathy
Apr 30, 2009: Unexpected Positive Finding Expands Potential For Quigley QR333 Drug For Diabetic Neuropathy
May 29, 2006: Quigley To Conduct Further Testing Of QR-435 For Ocular Herpes In Animals
Mar 29, 2004: Quigley Pharma Conducts Pre-IND Meeting With The FDA On Its Diabetic Peripheral Neuropathy Formulation
Dec 28, 2006: Quigley Announces Results of In-Vitro Studies For The Potential Treatment Of Herpes Keratitis And Next Steps For Its QR-435 Compound
Sep 26, 2006: Following Positive Data Shows QR-333 To Be Safe
Jun 25, 2005: The Quigley Corporation Announces Results Of Animal Model Inflammation Studies Of Its QR440 Botanical Anti-Inflammatory Compound
Jan 24, 2005: Quigley Pharma Announces Research And Development Update
Aug 21, 2006: Quigley Assigned Second Patent Covering Peripheral Neural And Vascular Ailments
Mar 21, 2006: Quigley Initiates Development Plan To Test QR-441 Against Avian Flu In Poultry Stocks
Nov 20, 2006: Quigley Pharma Commences QR-333 Phase IIb Clinical Study
Feb 20, 2007: The Quigley Corporation And The Israeli Ministry Of Agriculture (MOAG) Will Collaborate To Test Quigley Pharma QR-441 Broad Spectrum Anti-Viral Against Avian Flu H5N1 In Chickens
Feb 13, 2006: Quigley Pharma Anti-Viral Compound QR-435 Demonstrates Potent Antiviral Activity Against Ocular And Genital Herpes
Nov 12, 2008: Quigley Announces Completion Of Phase IIb Clinical Study Of QR-333 For Diabetic Peripheral Neuropathy On November 25, 2008
Sep 11, 2007: Quigley Corporation Releases Update On Quigley Pharma's Phase IIb Clinical Study Of QR-333 In Diabetic Peripheral Neuropathy
Apr 10, 2006: Quigley Commences Human Testing Of Its QR-333 Topical Diabetic Peripheral Neuropathy Investigational New Drug
Dec 08, 2005: Quigley Pharma's Compound QR-336 Shows To Protect Mice From Lethal Exposure To Ionizing Radiation
Aug 08, 2006: Quigley Pharma Compound QR-443 Effective
Mar 07, 2006: Quigley Submits Investigational New Drug Application To the FDA For Its QR-333 Diabetic Peripheral Neuropathy Compound
Apr 05, 2004: The Quigley Corporation's Proprietary Formula QR-336 Protects Mice In A Lethal-Dose Radiation Study.
Nov 03, 2005: The Quigley Corporation Retains Brocair Partners LLC To Provide Strategic Option Evaluations For Quigley Pharma's QR-340 Scar Formula
Oct 03, 2006: Quigley Radioprotective Compound QR-336 Shows To Be Most Effective In Oral And Subcutaneous Injection Dose Forms In Animal Model Study
Apr 03, 2006: Quigley Enlists Leading Radiation Oncology Researcher To Assists In The Development Plan And Radiological Testing Of QR-336 Compound
Mar 03, 2004: Professor Paul Valensi PresentS Research On Quigley's QR-333 At The Diabetes 2004 Conference In Nice France
Dec 01, 2005: Quigley Pharma's Compound QR-441 Shows To Increase Protectivity Against H5N1 Avian Flu When Impregnated In To Commercially Available Respiratory Face Masks
Aug 01, 2005: The Quigley Corporation Announces Positive In-Vitro Study Results Of Its QR440 Compound Support Conclusions Of Previous Animal Study Findings
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Quigley Pharma, Inc. – Pipeline by Therapy Area and Indication, H2 2011
Quigley Pharma, Inc. – Pipeline by Stage of Development, H2 2011
Quigley Pharma, Inc. – Monotherapy Products in Pipeline, H2 2011
Quigley Pharma, Inc. - Phase II, H2 2011
Quigley Pharma, Inc. - Pipeline By Therapeutic Class, H2 2011
Quigley Pharma, Inc. - Pipeline By Target, H2 2011
Quigley Pharma, Inc. – Pipeline By Route of Administration, H2 2011
Quigley Pharma, Inc. – Pipeline By Molecule Type, H2 2011
Quigley Pharma, Inc. - Dormant Developmental Projects, 2010

LIST OF FIGURES

Quigley Pharma, Inc. – Pipeline by Therapy Area and Indication, H2 2011
Quigley Pharma, Inc. – Pipeline by Stage of Development, H2 2011
Quigley Pharma, Inc. – Monotherapy Products in Pipeline, H2 2011
Quigley Pharma, Inc. – Pipeline By Therapeutic Class, H2 2011
Quigley Pharma, Inc. - Pipeline By Target, H2 2011
Quigley Pharma, Inc. – Pipeline By Route of Administration, H2 2011
Quigley Pharma, Inc. – Pipeline By Molecule Type, H2 2011

Ask Your Question

Quigley Pharma, Inc. – Product Pipeline Review – H2 2011
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: